RT Journal Article
SR Electronic
A1 Vinall, Maria
T1 Addition of Spironolactone to Ambrisentan May Be a Novel Treatment Strategy to Improve Outcome in Patients with PAH
JF MD Conference Express
YR 2013
FD SAGE Publications
VO 13
IS 4
SP 15
OP 16
DO 10.1177/155989771304007
UL http://mdc.sagepub.com/content/13/4/15.2.abstract
AB This article presents the results of a retrospective study that demonstrated a trend toward additional clinical improvement when spironolactone was added to ambrisentan for the treatment of patients with pulmonary arterial hypertension. This study analyzed data from patients in the double-blind, placebo-controlled Ambrisentan in Patients With Moderate to Severe Pulmonary Arterial Hypertension studies [ARIES-1 and −2; Galiè N et al. Circulation 2008].